Citigroup Reiterates Neutral Rating on Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
Citigroup analysts reiterated a Neutral rating on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) on February 06, 2026. Bristol-Myers Squibb Company PFD CONV 2 operates in the…
Read more
